Respiratoriske forstyrrelser forekom oftere hos abataceptbehandlede patienter end placebobehandlede (henholdsvis 10, 8% og 5, 9%).
Respiratory disorders occurred more frequently in abatacept-treated patients than in placebo-treated patients (10.8% vs.